|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Atopic eczema treatment now and in the future:Targeting the skin barrier and key immune mechanisms in human skin显示文摘The skin facilitates a number of key roles but its functioning can be impaired by disease. Atopic eczema is a chronic inflammatory disease where the skin barrier has become leaky, and inflammation occurs. It affects up to 20% of children and 3% of adults worldwide, manifesting as red itchy patches of skin with varying severity. This review aims to investigate the leaky skin barrier and immune mechanisms from the perspective of potential novel treatments. The complexity of atopic eczema as a disease is what makes it difficult to treat. Genome-wide association studies have highlighted possible genetic variations associated with atopic eczema, however in some cases, individuals develop the disease without these genetic risk factors. Loss of function mutations in the filaggrin gene are one of these associations and this is plausible due to its key role in barrier function. The Th2 immune response is the link with regards to the immune mechanisms as atopic inflammation often occurs through increased levels of interleukin(IL)-4 and IL-13. Eczematous inflammation also creates susceptibility to colonisation and damage by bacteria such as Staphylococcus aureus. Potential novel treatments are becoming ever more specific, offering the hope of fewer side effects and better disease control. The best new treatments highlighted in this review target the immune response with human beta defensin 2, phosphodiesterase-4 inhibitors and monoclonal antibodies all showing promise. | David C Bell Sara J Brown | 2017 | World Journal of Dermatology2017，6，3： | 5 |
| 2 | Skin-gut axis:The relationship between intestinal bacteria and skin health显示文摘The gut microbiome is an emerging area of interest in medicine. Imbalances in the gut microbiome have been linked to a number of disease states such as obesity and type 2 diabetes. The relationship between normally residing intestinal bacteria(the gut microbiota) and their potential role in the pathogenesis of skin diseases is an area of research for which we are only beginning to understand. Small studies have demonstrated underlying changes in the gut microbiome of patients with certain dermatological diseases. Interestingly, studies suggest that probiotics may have a role in the treatment of atopic dermatitis. However, the concept of the 'skin-gut axis' is a newly emerging and important avenue of investigation, still lacking in pathobiological explanations. This review will introduce and describe the intestinal microbiome as it relates to skin health in a complex communication network between the immune system, endocrine system, metabolic system, and nervous system. | Alexandra R Vaughn Manisha Notay Ashley K Clark Raja K Sivamani | 2017 | World Journal of Dermatology2017，6，4： | 4 |
| 3 | Uremic Pruritus: A Clinical Study of Maintenance Hemodialysis Patients显示文摘 | Jacek C. Szepietowski Magdalena Sikora Mariusz Kusztal Joanna Salomon Maria Magott Tomasz Szepietowski | 2002 | The Journal of Dermatology2002，，10： | 3 |
| 4 | Review of allergic contact dermatitis: Scratching the surface显示文摘Contact dermatitis-including allergic contact dermatitis(ACD)-n and results in over four million lost work days per year in the United States alone. ACD is a classic example of a type IV delayed hypersensitivity reaction, and represents a significant burden on the health system, economy, and patient quality of life. Thorough history taking, clinical examination, histologic evaluation, and patch testing are keys to diagnosing contact dermatitis. Patch testing, especially with comprehensive and customized panels based on the patient's exposure history, is particularly useful in identifying potential allergens inthe case of allergic contact dermatitis. ACD management requires a combination of direct medical intervention, patient education, and appropriate environmental modification to prevent exposure to offending allergens in the home or workplace. Continuing advances in the study of ACD has led to an increased understanding of the disease processes, new methods for diagnosis, and improved management. This article reviews ACD-aiming to connect recent investigational data with the current clinical understanding of disease pathophysiology, diagnostic techniques, and management strategies. | Gil S Weintraub Isabella Nga Lai Christina N Kim | 2015 | World Journal of Dermatology2015，4，2： | 3 |
| 5 | The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity; persisting areas of confusion显示文摘 | P.C.M.Kerkhof | 2006 | British Journal of Dermatology2006，，4： | 2 |
| 6 | Pathogenesis and diagnosis of contact dermatitis:Applications of reflectance confocal microscopy显示文摘Contact dermatitis(CD) is the most common professional skin disease, with frequencies ranging from 24 to 170 every 100000 individuals. Approximately 20% of the United States population suffers from CD. CD can be classified according to its origin and severity. ICD stands for irritant CD, whereas ACD means allergic CD. Their clinical presentation includes acute, sub-acute and chronic eczema. Despite their different origin, ICD and ACD often present similar clinical and histologic findings. The current gold standard for diagnosis is patchtesting. However, patch-testing is being questioned in terms of validity and reproducibility, as it relies heavily on the skill of the observer. Real-time reflectance confocal microscopy is a non-invasive imaging technique that bears strong promise for the study of CD, and it enables the evaluation of cellular and subcellular changes over time with similar resolution compared to that of conventional histology. | Jorge A Suárez-Pérez Ricardo Bosch Salvador González Ernesto González | 2014 | World Journal of Dermatology2014，3，3： | 2 |
| 7 | The nude mouse model for the study of human skin disorders显示文摘 | Gilhar A Etzioni A | 1994 | Dermatology1994，189，1： | 2 |
| 8 | Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature显示文摘 | ChristineKilcline Ilona J.Frieden | 2008 | Pediatric Dermatology2008，，2： | 2 |
| 9 | Possible benefit from treatment of Helicobacter pylori in antihistamine‐resistant chronic urticaria显示文摘 | E. Magen J. Mishal | 2012 | Clinical dermatology2012，，1： | 2 |
| 10 | New insights into rosacea pathophysiology: A review of recent findings显示文摘 | Martin Steinhoff Jürgen Schauber James J. Leyden | 2013 | Journal of the American Academy of Dermatology2013，，6： | 2 |
| 11 | Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus显示文摘 | Lasse R. Braathen Rolf-Markus Szeimies Nicole Basset-Seguin Robert Bissonnette Peter Foley David Pariser Rik Roelandts Ann-Marie Wennberg Colin A. Morton | 2007 | Journal of the American Academy of Dermatology2007，，： | 2 |
| 12 | Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study显示文摘Objective:Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A and is approved for treating moderate-to-severe psoriasis.This phase 3,multicenter,randomized,double-blind,placebo-controlled trial(NCT03364309;registered December 6,2017)evaluated the safety and efficacy of ixekizumab in Chinese patients with moderate-to-severe psoriasis.Methods:438 patients were randomized 2:2:1 to 80 mg ixekizumab every 2 weeks(IXE Q2W,n=176),80 mg ixekizumab every 4 weeks(IXE Q4W,n=174),or placebo(n=88).Efficacy was assessed by evaluating the static Physician’s Global Assessment score of 0 or 1(sPGA[0,1])and Psoriasis Area and Severity Index(PASI)75/90/100 responses,and nonresponder imputation was used for handling missing data.The safety profile was evaluated by assessing treatment emergent adverse events(AEs)and serious AEs.Results:At week 12,the sPGA(0,1)response rates were 3.4%,79.9%,and 86.4%in the placebo,IXE Q4W,and IXE Q2W groups,respectively.The PASI 75/90/100 response rates were 8.0%/2.3%/0.0%,87.4%/75.9%/29.3%,and 93.8%/82.4%/33.0%in the placebo,IXE Q4W,and IXE Q2W groups,respectively.Ixekizumab led to rapid PASI 50 responses,as early as week 1,whereas PASI 75 and sPGA(0,1)responses were observed from week 2.sPGA(0,1)and sPGA(0)responses were maintained through week 60 in a higher proportion of patients receiving IXE Q4W vs.placebo.The safety profile was consistent with previous studies of ixekizumab in psoriasis.Conclusion:Ixekizumab showed a rapid onset of action and high efficacy that was maintained through 60 weeks and was well tolerated with no unexpected AEs,in Chinese patients with moderate-to-severe plaque psoriasis. | Xia Li Jie Zheng Wei-Li Pan Min Zheng Yan Lu Fu-Qiu Li Yang-Feng Ding Jian-Zhong Zhang Hong-Ying Li Wen-Long Rui | 2022 | International Journal of Dermatology and Venereology2022，5，4： | 2 |
| 13 | Recent Advances in Acne Pathogenesis: Implications for Therapy显示文摘 | Shinjita Das Rachel V. Reynolds | 2014 | American Journal of Clinical Dermatology2014，，6： | 2 |
| 14 | Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy 显示文摘 | DEVOS S A VANDEN B N DEVOS M | 2003 | Dermatology2003，206，4： | 2 |
| 15 | Impaired Ultraviolet-B-Induced Cytokine Induction in Xeroderma Pigmentosum Fribroblasts显示文摘 | Suzuki H Kalair W Shivji GM | 2001 | The Journal of Investigative Dermatology2001，117，5： | 2 |
| 16 | Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms显示文摘 | Luis Requena Omar P. Sangueza | 1998 | Journal of the American Academy of Dermatology1998，，2： | 2 |
| 17 | Recurrent aphthous stomatitis显示文摘 | Terry D Rees D | 1996 | Dermatologic Clinic1996，14，2： | 2 |
| 18 | Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response显示文摘 | Robert H. Rosen Aditya K. Gupta Stephen K. Tyring | 2011 | Journal of the American Academy of Dermatology2011，，： | 2 |
| 19 | Clinical accuracy of the diagnosis of cutaneous malignant melanoma显示文摘 | MorTon CA Mackie RM | 1998 | Bri J Dermatology1998，138，： | 2 |
| 20 | Human mesenchymal stem cells successfully improve skin‐substitute wound healing显示文摘 | H.Nakagawa S.Akita M.Fukui T.Fujii K.Akino | 2005 | British Journal of Dermatology2005，，1： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员